SCHEMBL760965

SCHEMBL760965

Nc1ccc2c(c1)C(=O)c1ccccc1-2

nearest known ligand 0.95

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.95
RAB9A P51151 6/20 0.95
SMN1; SMN2 Q16637 5/20 0.95
ALDH1A1 P00352 5/20 0.95
MAPK1 P28482 4/20 0.95
CYP3A4 P08684 2/20 0.95
TSHR P16473 2/20 0.95
TP53 P04637 1/20 0.95
TDP1 Q9NUW8 1/20 0.95
PTPRC P08575 4/20 0.91
MEN1 O00255 3/20 0.91
KMT2A Q03164 3/20 0.91
S100A4 P26447 3/20 0.91
LMNA P02545 3/20 0.91
PLA2G1B P04054 3/20 0.91
ATG4B Q9Y4P1 3/20 0.91
APAF1 O14727 2/20 0.91
TDP2 O95551 2/20 0.91
POLB P06746 2/20 0.91
PLCG1 P19174 2/20 0.91

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30482647 1.00 NPC1 (0.95) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL31615519 1.00 NPC1 (0.95) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
Anthraquinone SCHEMBL23363689 0.98 NPC1 (1.00) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL40960 0.98 NPC1 (1.00) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL31290097 0.98 NPC1 (1.00) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL30043508 0.95 PTPRC (1.00) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
Benzene SCHEMBL28832927 0.95 NPC1 (0.95) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL1143226 0.95 PTPRC (0.91) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL2599178 0.95 PTPRC (1.00) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1
SCHEMBL6262683 0.91 PTPRC (1.00) NPC1RAB9ASMN1; SMN2ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118834119-A Method for synthesizing bisphenol compound by catalysis of supported ionic liquid 郑州中科新兴产业技术研究院 2024-10-25 CN claimed
CN-117756619-A 3-bromofluorenone and preparation method thereof 维思普新材料(苏州)有限公司 2024-03-26 CN claimed
CN-111885914-A Compositions and methods for producing expanded hematopoietic stem cells using fluorene derivatives 投资健康有限责任公司 2020-11-03 CN claimed
EP-3700334-A1 COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE Transfusion Health, LLC (US) 2020-09-02 EP claimed
US-20200255371-A1 COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE IMMUNEBRIDGE LLC 2020-08-13 US claimed
CN-1139606-C Norbornene catalytic system and its preparation method and application 中国科学院化学研究所 2004-02-25 CN claimed
CN-1394685-A Norbornene catalytic system and its preparation method and application CHINESE ACAD INST CHEMISTRY (CN) 2003-02-05 CN claimed
EP-0410287-B1 Polyphosphazene derivatives containing carbonyl groups and variously alkylated tertiary amino groups CONSIGLIO NAZIONALE RICERCHE (IT) 1995-11-02 EP claimed
EP-0430434-B1 Process for the preparation of fluoroaromatic and fluoroheteroaromatic compounds ZENECA LTD (GB) 1994-09-14 EP claimed
WO-1993014062-A1 ANTHELMINTIC β-KETOAMIDES THE UPJOHN COMPANY (US) 1993-07-22 WO claimed
EP-0430434-A2 Process for the preparation of fluoroaromatic and fluoroheteroaromatic compounds ZENECA LIMITED (GB) 1991-06-05 EP claimed
EP-0410287-A2 Polyphosphazene derivatives containing carbonyl groups and variously alkylated tertiary amino groups CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 1991-01-30 EP claimed
JP-60084253-A None JP disclosed
JP-62059934-A None JP disclosed
US-20260139710-A1 BEARING DEVICE, METHOD OF MANUFACTURING BEARING DEVICE, HARD DISK DRIVE DEVICE, AND MOTOR MINEBEA MITSUMI INC (JP) 2026-05-21 US disclosed
CN-122062050-A Bearing device, method for manufacturing bearing device, hard disk drive device, and motor 美蓓亚三美株式会社 2026-05-19 CN disclosed
EP-0124891-A2 Antimutagenic agent and method of inactivating the mutagenicity of foods and beverages by using said agent SUNTORY LIMITED (JP) 1984-11-14 EP disclosed
US-4436745-A TETRACYCLIC SPIROHYDANTOINS ALCON LABORATORIES, INC. (US) 1984-03-13 US disclosed
WO-1983003543-A1 METHOD OF INHIBITING ALDOSE REDUCTASE ACTIVITY, COMPOSITIONS THEREFOR AND PROCESS FOR PREPARING SPIRO-FLUOROFLUOREN AND SPIRO-DIFLUOROFLUOREN COMPOUNDS ALCON LAB INC (US) 1983-10-27 WO disclosed
EP-0092385-A2 Hydantoin derivatives for use in inhibiting aldose reductase activity, compositions therefor and process for preparing spiro-fluoren compounds ALCON LABORATORIES, INC. (US) 1983-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255371-A1 COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE FLI1, MCL1, HCLS1 NPC1 709/4885RAB9A 775/4885SMN1; SMN2 544/4885
US-20260139710-A1 BEARING DEVICE, METHOD OF MANUFACTURING BEARING DEVICE, HARD DISK DRIVE DEVICE, AND MOTOR ZW10, SOD1, EED NPC1 4386/4885RAB9A 489/4885SMN1; SMN2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.